https://www.selleckchem.com/products/a-485.html
In this retrospective trial, we analyzed data of patients with relapsed/refractory lymphoma who received outpatient fractionated ICE between 2011-2017 at a tertiary care center. The three weekly ICE protocol consisted of ifosfamide 1500 mg/m infused over 2 h on days 1-3, carboplatin (5 AUC) on day 1, and etoposide 100 mg/m on days 1-3. Rituximab 375 mg/m was given to patients with CD20 positive B cell Non-Hodgkin lymphoma. Total of 89 patients were included in this research project. Majority of patients had Hodgkin lymphoma (64%). Mean nu